Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1996年 / 34卷 / 02期
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 18 条
[1]   A PHASE-III STUDY OF ACCELERATED RADIOTHERAPY WITH AND WITHOUT CARBOPLATIN IN NONSMALL CELL LUNG-CANCER - AN INTERIM TOXICITY ANALYSIS OF THE FIRST 100 PATIENTS [J].
BALL, D ;
BISHOP, J ;
SMITH, J ;
CRENNAN, E ;
OBRIEN, P ;
DAVIS, S ;
RYAN, G ;
JOSEPH, D ;
WALKER, Q .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (02) :267-272
[2]   A PHASE-I/II STUDY TO EVALUATE ACCELERATED FRACTIONATION VIA CONCOMITANT BOOST FOR SQUAMOUS, ADENO, AND LARGE-CELL CARCINOMA OF THE LUNG - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 84-07 [J].
BYHARDT, RW ;
PAJAK, TF ;
EMAMI, B ;
HERSKOVIC, A ;
DOGGETT, RS ;
OLSEN, LA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (03) :459-468
[3]   INTERFRACTION INTERVAL IS A MAJOR DETERMINANT OF LATE EFFECTS, WITH HYPERFRACTIONATED RADIATION-THERAPY OF CARCINOMAS OF UPPER RESPIRATORY AND DIGESTIVE TRACTS - RESULTS FROM RADIATION-THERAPY ONCOLOGY GROUP PROTOCOL 8313 [J].
COX, JD ;
PAJAK, TF ;
MARCIAL, VA ;
COIA, L ;
MOHIUDDIN, M ;
FU, KK ;
SELIM, H ;
RUBIN, P ;
ORTIZ, H .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (06) :1191-1195
[4]   A RANDOMIZED PHASE-I/II TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH TOTAL DOSES OF 60.0 GY TO 79.2 GY - POSSIBLE SURVIVAL BENEFIT WITH GREATER-THAN-OR-EQUAL-TO 69.6 GY IN FAVORABLE PATIENTS WITH RADIATION-THERAPY ONCOLOGY GROUP STAGE-III NON-SMALL-CELL LUNG-CARCINOMA - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 83-11 [J].
COX, JD ;
AZARNIA, N ;
BYHARDT, RW ;
SHIN, KH ;
EMAMI, B ;
PAJAK, TF .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1543-1555
[6]   ARE HALF-TIMES OF REPAIR RELIABLY SHORTER FOR TUMORS THAN FOR LATE NORMAL-TISSUE EFFECTS [J].
FOWLER, JF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (01) :189-190
[7]  
Hopewell J W, 1988, Br J Radiol Suppl, V22, P88
[8]   RANDOMIZED TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH OR WITHOUT CONCURRENT CHEMOTHERAPY FOR STAGE-III NON-SMALL-CELL LUNG-CANCER [J].
JEREMIC, B ;
SHIBAMOTO, Y ;
ACIMOVIC, L ;
DJURIC, L .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :452-458
[9]   HYPERFRACTIONATED RADIATION-THERAPY (HFX RT) FOLLOWED BY MULTIAGENT CHEMOTHERAPY (CHT) IN PATIENTS WITH MALIGNANT GLIOMA - A PHASE-II STUDY [J].
JEREMIC, B ;
GRUJICIC, D ;
ANTUNOVIC, V ;
DJURIC, L ;
STOJANOVIC, M ;
SHIBAMOTO, Y .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (05) :1179-1185
[10]   RADIOTHERAPY OF THE RHABDOMYOSARCOMA R1H OF THE RAT - INFLUENCE OF THE TIME-INTERVAL BETWEEN 2 DAILY FRACTIONS DURING HYPERFRACTIONATED RADIOTHERAPY [J].
KLEINEIDAM, M ;
PIECONKA, A ;
BECKBORNHOLDT, HP .
RADIOTHERAPY AND ONCOLOGY, 1994, 30 (02) :128-132